DE69832165D1 - Hgf zur behandlung von akutem nierenversagen - Google Patents

Hgf zur behandlung von akutem nierenversagen

Info

Publication number
DE69832165D1
DE69832165D1 DE69832165T DE69832165T DE69832165D1 DE 69832165 D1 DE69832165 D1 DE 69832165D1 DE 69832165 T DE69832165 T DE 69832165T DE 69832165 T DE69832165 T DE 69832165T DE 69832165 D1 DE69832165 D1 DE 69832165D1
Authority
DE
Germany
Prior art keywords
hgf
treatment
kidney failure
acute kidney
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832165T
Other languages
English (en)
Other versions
DE69832165T2 (de
Inventor
Ikue Mori
Tomokazu Nagano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69832165D1 publication Critical patent/DE69832165D1/de
Application granted granted Critical
Publication of DE69832165T2 publication Critical patent/DE69832165T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69832165T 1997-03-15 1998-03-12 Hgf zur behandlung von akutem nierenversagen Expired - Lifetime DE69832165T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8223597 1997-03-15
JP8223597 1997-03-15
PCT/JP1998/001081 WO1998041227A1 (en) 1997-03-15 1998-03-12 Hgf for treating acute renal failure

Publications (2)

Publication Number Publication Date
DE69832165D1 true DE69832165D1 (de) 2005-12-08
DE69832165T2 DE69832165T2 (de) 2006-04-20

Family

ID=13768753

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69832165T Expired - Lifetime DE69832165T2 (de) 1997-03-15 1998-03-12 Hgf zur behandlung von akutem nierenversagen

Country Status (8)

Country Link
US (1) US6436388B2 (de)
EP (1) EP0979097B1 (de)
JP (2) JP4865936B2 (de)
AT (1) ATE308337T1 (de)
AU (1) AU6311498A (de)
DE (1) DE69832165T2 (de)
TW (1) TW527190B (de)
WO (1) WO1998041227A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289795T3 (es) * 1997-12-03 2008-02-01 Nakamura, Toshikazu Preparacion para administracion intravenosa continua.
US6887477B1 (en) * 1998-08-05 2005-05-03 Tomokazu Nagano Method of treating ischemic disease by intramuscular administration of Hepatocyte growth factor
US7612046B2 (en) 2000-01-31 2009-11-03 Uwe Waldemar Rothenpieler Method for treating kidney disorders
EP1255569B1 (de) * 2000-01-31 2010-09-15 Uwe Waldemar Rothenpieler Pax2 zur behandlung von nierenkrankheiten
US8048806B2 (en) 2000-03-17 2011-11-01 Applied Materials, Inc. Methods to avoid unstable plasma states during a process transition
US8617351B2 (en) 2002-07-09 2013-12-31 Applied Materials, Inc. Plasma reactor with minimal D.C. coils for cusp, solenoid and mirror fields for plasma uniformity and device damage reduction
US7601365B2 (en) 2000-08-28 2009-10-13 Damavand Wound, AB Synergetic effects of HGF and antibacterial treatment
TWI283899B (en) * 2002-07-09 2007-07-11 Applied Materials Inc Capacitively coupled plasma reactor with magnetic plasma control
US7125835B2 (en) * 2002-10-10 2006-10-24 International Flavors & Fragrances Inc Encapsulated fragrance chemicals
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091180A (en) * 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
JPH03255096A (ja) 1990-03-01 1991-11-13 Toyobo Co Ltd 組換ラット肝実質細胞増殖因子
JP2777678B2 (ja) 1990-06-11 1998-07-23 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法
JP2750372B2 (ja) 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
US5360790A (en) * 1990-12-11 1994-11-01 The Regents Of The University Of Michigan Method and formulations for the therapy of acute renal failure
DE69310525T2 (de) * 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
WO1997012629A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Improved angiogenesis using hepatocyte growth factor
JP3255096B2 (ja) 1997-10-01 2002-02-12 株式会社ニコン 露光装置及び露光方法

Also Published As

Publication number Publication date
JP2010100664A (ja) 2010-05-06
TW527190B (en) 2003-04-11
WO1998041227A1 (en) 1998-09-24
US20010047079A1 (en) 2001-11-29
ATE308337T1 (de) 2005-11-15
EP0979097B1 (de) 2005-11-02
US6436388B2 (en) 2002-08-20
EP0979097A1 (de) 2000-02-16
JP4865936B2 (ja) 2012-02-01
JP2001516358A (ja) 2001-09-25
DE69832165T2 (de) 2006-04-20
AU6311498A (en) 1998-10-12

Similar Documents

Publication Publication Date Title
DE69616333T2 (de) Thip zur behandlung von schlafstörungen
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE308337T1 (de) Hgf zur behandlung von akutem nierenversagen
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
EA199900124A2 (ru) Способ лечения сердечной недостаточности
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
DE69313872D1 (de) Verbindung von nucleocidanaloga zur behandlung viraler infektionen
DE69802918D1 (de) Vwf propeptide enthaltendes pharmazeutisches präparat
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69607559T2 (de) Verfahren zur Behandlung von Phenolteer
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE69218200D1 (de) Behandlung von leberkrebs
DE69330465T2 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE69917445D1 (de) Reinigung von carboxaldehyd
DK0517787T3 (da) Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
NO990436L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
ATE486594T1 (de) Methode zur behandlung von herzinsuffizienz
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE74004T1 (de) Mischung zur behandlung von hypercholesterolemie.
DE69927591D1 (de) Behandlung von nierenkolik mit gaba-analogen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition